HELP vs MMED: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HELP and MMED share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HELP and MMED exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cybin Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and adopted the operating name Helus Pharma, is a Toronto-based clinical-stage pharmaceutical company. Its lead program is HLP003 (also referenced as CYB003), a deuterated psilocybin analog being studied as an adjunctive treatment for major depressive disorder in a pivotal Phase 3 program called PARADIGM, which includes the APPROACH and EMBRACE studies. A second candidate, HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. These are neuroactive serotonergic molecules designed to be administered in a supervised clinical setting.

Full HELP guide

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company building treatments for brain-health and psychiatric disorders from psychedelic and related compounds. Its lead asset is DT120 (formerly MM120), a pharmaceutically optimized, orally disintegrating tablet form of lysergide (LSD) D-tartrate being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). A Phase 2b study met its endpoints with durable anxiety improvement to Week 12, and the program carries FDA Breakthrough Therapy Designation for GAD, with results published in JAMA. The company also has earlier-stage programs including MM402 (an R-MDMA candidate) for autism spectrum disorder. In January 2026 the company rebranded to Definium Therapeutics and its Nasdaq ticker changed from MNMD to DFTX (the MMED symbol traced to its earlier Canadian listing).

Full MMED guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HELP drivers: Phase 3 depression readout; Anxiety program optionality.
• MMED drivers: Three Phase 3 readouts in 2026; Deep cash runway.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. For MMED, the company is unprofitable and cash-burning, with a Q1 2026 net loss reported near $77M (inflated by non-cash warrant fair-value changes) on operating expenses around $59M and no product revenue, so the multi-billion-dollar market value rests entirely on future clinical and regulatory success rather than current fundamentals.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HELP if you believe its drivers more; MMED if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HELP and MMED guides.

HELP. Standard earnings multiples do not apply because Cybin has essentially no revenue and runs at a loss while funding Phase 3 trials. Much of its roughly $257 million market value is backed by its cash balance of around $195 million, so the market is assigning only a modest premium for the pipeline ahead of pivotal data. Valuation will hinge on trial outcomes and any resulting financing rather than on current financials.

MMED. Mind Medicine (Definium) has no P/E because it is pre-revenue and unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality: only a fraction of the several-billion-dollar market value is backed by cash, with the remainder pricing the probability-weighted outcome of the 2026 Phase 3 readouts. Revenue is zero, which is normal for a clinical-stage biotech but means the shares trade on catalysts, not fundamentals. The reported Q1 net loss was materially distorted by a non-cash change in the fair value of financing warrants tied to the share-price rise, so operating cash burn is a better gauge of spending.

Headline figures (approximate, July 2026): HELP shows share price ~$5, market cap ~$257M, revenue (ttm) ~$0 (pre-revenue, under $1M), cash ~$195M (end of 2025); MMED shows market cap ~$4.7B (mid-2026), product revenue ~$0 (pre-commercial), net loss (q1 2026) ~$77M (incl. non-cash warrant charge), operating expenses (q1 2026) ~$59M (R&D ~$42M, G&A ~$18M).

HELP and MMED are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HELP and MMED exposure against your real portfolio. It is not an investment adviser.